A Microphysiological HHT-on-a-Chip Platform Recapitulates Patient Vascular Lesions

Area of Science:

• Biomedical Engineering
• Vascular Biology
• Rare Disease Modeling

Background:

• Hereditary Hemorrhagic Telangiectasia (HHT) is a rare genetic disorder causing fragile vascular malformations and bleeding.
• Current understanding of HHT pathogenesis, particularly the role of Endoglin (ENG) and Alk1 (ACVRL1) mutations, remains incomplete.
• Existing animal models have limitations in fully recapitulating human HHT pathology.

Conclusions:

• The developed HHT-VMO is a novel, human cell-based model that accurately reproduces HHT vascular lesions.
• The model provides insights into HHT disease biology, including the critical role of Alk1 during vascular development.
• The HHT-VMO platform is a valuable tool for understanding HHT pathogenesis and for identifying and testing new therapeutic strategies.